{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:14:09Z","timestamp":1792818849568,"version":"4.5.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":337,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["PSAU\/2024\/R\/1445"],"award-info":[{"award-number":["PSAU\/2024\/R\/1445"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease is the most prevalent form of dementia in the elderly, which is clinically characterized by a gradual and progressive deterioration of cognitive functions. The central and early role of \u03b2-amyloid in the pathogenesis of Alzheimer\u2019s disease is supported by a plethora of studies including genetic analyses, biomarker research and genome-wide association studies in both familial (early-onset) and sporadic (late-onset) forms of Alzheimer\u2019s. Monoclonal antibodies directed against \u03b2-amyloid demonstrate slowing of the clinical deterioration of patients with early Alzheimer\u2019s disease. Aducanumab, lecanemab and donanemab clinical trials showed slowing of Alzheimer\u2019s disease progression on composite scores by 25\u201340% based on the measure used. Anti-\u03b2-amyloid antibodies can cause side effects of bleeding and swelling in the brain, called amyloid-related imaging abnormalities. Amyloid-related imaging abnormalities typically occur early in treatment and are often asymptomatic, and though in rare cases, they can lead to serious or life-threatening events. The aim of this review is to evaluate the clinical meaningfulness of anti-\u03b2-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer\u2019s disease.<\/jats:p>","DOI":"10.1093\/braincomms\/fcae435","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T15:26:36Z","timestamp":1732893996000},"source":"Crossref","is-referenced-by-count":24,"title":["Evaluating clinical meaningfulness of anti-\u03b2-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer\u2019s disease"],"prefix":"10.1093","volume":"6","author":[{"given":"Manal","family":"Aljuhani","sequence":"first","affiliation":[{"name":"Radiological Science and Medical Imaging Department, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University , Al-Kharj 11942 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhaar","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Brain Sciences, Faculty of Medicine, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-2002","authenticated-orcid":false,"given":"Paul","family":"Edison","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Brain Sciences, Faculty of Medicine, Imperial College London , London W12 0NN ,","place":["UK"]},{"name":"Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University , Wales CF24 4HQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"issue":"1","key":"2024122016293922200_fcae435-B1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2024122016293922200_fcae435-B2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","article-title":"Alzheimer\u2019s disease and Down\u2019s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein","volume":"122","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2024122016293922200_fcae435-B3","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5580","key":"2024122016293922200_fcae435-B4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"issue":"2","key":"2024122016293922200_fcae435-B5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"2024122016293922200_fcae435-B6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2024122016293922200_fcae435-B7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2024122016293922200_fcae435-B8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2024122016293922200_fcae435-B9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Petersen","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"2024122016293922200_fcae435-B10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000354370","article-title":"Rate of conversion from prodromal Alzheimer\u2019s disease to Alzheimer\u2019s dementia: A systematic review of the literature","volume":"3","author":"Ward","year":"2013","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"10","key":"2024122016293922200_fcae435-B11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jamda.2016.06.020","article-title":"Spontaneous reversion of mild cognitive impairment to normal cognition: A systematic review of literature and meta-analysis","volume":"17","author":"Canevelli","year":"2016","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"2024122016293922200_fcae435-B12","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2024122016293922200_fcae435-B13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer\u2019s disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2024122016293922200_fcae435-B14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00401-018-1846-7","article-title":"Diffusible, highly bioactive oligomers represent a critical minority of soluble Abeta in Alzheimer\u2019s disease brain","volume":"136","author":"Hong","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"8","key":"2024122016293922200_fcae435-B15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"issue":"2","key":"2024122016293922200_fcae435-B16","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"18","key":"2024122016293922200_fcae435-B17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2024122016293922200_fcae435-B18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2024122016293922200_fcae435-B19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"2024122016293922200_fcae435-B20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"2024122016293922200_fcae435-B21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2024122016293922200_fcae435-B22","first-page":"362","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"11","key":"2024122016293922200_fcae435-B23","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): Radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"4","key":"2024122016293922200_fcae435-B24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2024122016293922200_fcae435-B25","doi-asserted-by":"crossref","first-page":"e12411","DOI":"10.1002\/trc2.12411","article-title":"Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer\u2019s disease: Open peer commentary","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"2024122016293922200_fcae435-B26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"35","key":"2024122016293922200_fcae435-B27","doi-asserted-by":"crossref","first-page":"14745","DOI":"10.1073\/pnas.0905127106","article-title":"Structure-neurotoxicity relationships of amyloid beta-protein oligomers","volume":"106","author":"Ono","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024122016293922200_fcae435-B28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic Abeta oligomer and Alzheimer\u2019s disease: An emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat Neurosci"},{"issue":"36","key":"2024122016293922200_fcae435-B29","doi-asserted-by":"crossref","first-page":"e2309389120","DOI":"10.1073\/pnas.2309389120","article-title":"A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer\u2019s disease","volume":"120","author":"Chen","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2024122016293922200_fcae435-B30","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/brain\/awad049","article-title":"An anti-amyloid therapy works for Alzheimer\u2019s disease: Why has it taken so long and what is next?","volume":"146","author":"Hardy","year":"2023","journal-title":"Brain"},{"issue":"1","key":"2024122016293922200_fcae435-B31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"2024122016293922200_fcae435-B32","doi-asserted-by":"crossref","first-page":"q1327","DOI":"10.1136\/bmj.q1327","article-title":"Donanemab: FDA experts recommend approval of Alzheimer\u2019s drug","volume":"385","author":"Dyer","year":"2024","journal-title":"BMJ"},{"key":"2024122016293922200_fcae435-B33","first-page":"128","article-title":"A light at the end of the tunnel\u2014From mutation identification to a potential treatment for Alzheimer\u2019s disease","author":"Lannfelt","year":"2023","journal-title":"Ups J Med Sci"},{"issue":"4","key":"2024122016293922200_fcae435-B34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"issue":"3","key":"2024122016293922200_fcae435-B35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1532-5415.2008.02122.x","article-title":"Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia","volume":"57","author":"Molnar","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"2024122016293922200_fcae435-B36","doi-asserted-by":"crossref","first-page":"e0179521","DOI":"10.1371\/journal.pone.0179521","article-title":"Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations","volume":"12","author":"Webster","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"2024122016293922200_fcae435-B37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/77.4.371","article-title":". Methods to explain the clinical significance of health status measures","volume":"77","author":"Guyatt","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"2024122016293922200_fcae435-B38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"2024122016293922200_fcae435-B39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000017201","article-title":"Key methodological features of randomized controlled trials of Alzheimer\u2019s disease therapy. Minimal clinically important difference, sample size and trial duration","volume":"10","author":"Burback","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8","key":"2024122016293922200_fcae435-B40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/gps.2607","article-title":"Determining the minimum clinically important differences for outcomes in the DOMINO trial","volume":"26","author":"Howard","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"2024122016293922200_fcae435-B41","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1474-4422(08)70087-5","article-title":"Endpoints for trials in Alzheimer\u2019s disease: A European task force consensus","volume":"7","author":"Vellas","year":"2008","journal-title":"Lancet Neurol"},{"issue":"3","key":"2024122016293922200_fcae435-B42","first-page":"507","article-title":"Clinical trial endpoints and their clinical meaningfulness in early stages of Alzheimer\u2019s disease","volume":"9","author":"Cohen","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"20","key":"2024122016293922200_fcae435-B43","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2024122016293922200_fcae435-B44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","article-title":"Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers","volume":"11","author":"Salvado","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"2024122016293922200_fcae435-B45","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","article-title":"Temporal dynamics of beta-amyloid accumulation in aging and Alzheimer disease","volume":"96","author":"Jagust","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"2024122016293922200_fcae435-B46","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1212\/WNL.0000000000011214","article-title":"Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation","volume":"96","author":"Farrell","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"2024122016293922200_fcae435-B47","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","article-title":"Relationship between amyloid and tau levels and its impact on tau spreading","volume":"48","author":"Dore","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2024122016293922200_fcae435-B48","first-page":"595","article-title":"\u2018Time saved\u2019 as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings","volume":"10","author":"Dickson","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"2024122016293922200_fcae435-B49","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40120-023-00473-w","article-title":"A path to improved Alzheimer\u2019s care: Simulating long-term health outcomes of lecanemab in early Alzheimer\u2019s disease from the CLARITY AD trial","volume":"12","author":"Monfared","year":"2023","journal-title":"Neurol Ther"},{"issue":"3","key":"2024122016293922200_fcae435-B50","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","article-title":"The potential economic value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","volume":"11","author":"Monfared","year":"2022","journal-title":"Neurol Ther"},{"issue":"4","key":"2024122016293922200_fcae435-B51","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","article-title":"Determining clinically meaningful decline in preclinical Alzheimer disease","volume":"93","author":"Insel","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"2024122016293922200_fcae435-B52","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2024122016293922200_fcae435-B53","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/alz.12768","article-title":"Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta-analysis","volume":"19","author":"Pang","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"19","key":"2024122016293922200_fcae435-B54","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"issue":"3","key":"2024122016293922200_fcae435-B55","doi-asserted-by":"crossref","first-page":"fcad175","DOI":"10.1093\/braincomms\/fcad175","article-title":"Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer\u2019s disease","volume":"5","author":"Liu","year":"2023","journal-title":"Brain Commun"},{"issue":"9","key":"2024122016293922200_fcae435-B56","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/ene.15007","article-title":"Brain volume loss due to donanemab","volume":"28","author":"Ayton","year":"2021","journal-title":"Eur J Neurol"},{"issue":"20","key":"2024122016293922200_fcae435-B57","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-beta-amyloid drugs: A systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"2024122016293922200_fcae435-B58","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/brain\/awx057","article-title":"Biochemically-defined pools of amyloid-beta in sporadic Alzheimer\u2019s disease: Correlation with amyloid PET","volume":"140","author":"Roberts","year":"2017","journal-title":"Brain"},{"issue":"6","key":"2024122016293922200_fcae435-B59","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.neuropsychologia.2008.02.015","article-title":"Neuropsychological correlates of whole brain atrophy in Alzheimer\u2019s disease","volume":"46","author":"Schott","year":"2008","journal-title":"Neuropsychologia"},{"issue":"1","key":"2024122016293922200_fcae435-B60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3233\/JAD-190623","article-title":"Volume analysis of brain cognitive areas in Alzheimer\u2019s disease: Interim 3-year results from the ASCOMALVA trial","volume":"76","author":"Traini","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2024122016293922200_fcae435-B61","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2024122016293922200_fcae435-B62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","article-title":"Amyloid-beta (Abeta) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer\u2019s disease mice","volume":"18","author":"Taylor","year":"2023","journal-title":"Mol Neurodegener"},{"issue":"2","key":"2024122016293922200_fcae435-B63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JAD-2011-101809","article-title":"Neuropathology and amyloid-beta spectrum in a bapineuzumab immunotherapy recipient","volume":"24","author":"Roher","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"2024122016293922200_fcae435-B64","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-014-1340-9","article-title":"Abeta immunotherapy for Alzheimer\u2019s disease: Effects on apoE and cerebral vasculopathy","volume":"128","author":"Sakai","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"10","key":"2024122016293922200_fcae435-B65","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaneurol.2020.1782","article-title":"Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation","volume":"77","author":"Regenhardt","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024122016293922200_fcae435-B66","doi-asserted-by":"crossref","first-page":"641734","DOI":"10.3389\/fmolb.2021.641734","article-title":"Role of interleukin-6 in vascular health and disease","volume":"8","author":"Villar-Fincheira","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"9","key":"2024122016293922200_fcae435-B67","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.04.015","article-title":"Cerebral amyloid angiopathy associated with inflammation: Report of 3 cases and systematic review","volume":"24","author":"Castro Caldas","year":"2015","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"4","key":"2024122016293922200_fcae435-B68","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2024122016293922200_fcae435-B69","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"2024122016293922200_fcae435-B70","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","article-title":"Aducanumab: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"2024122016293922200_fcae435-B71","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3233\/JAD-220841","article-title":"Amyloid PET: A questionable single primary surrogate efficacy measure on Alzheimer immunotherapy trials","volume":"90","author":"Hoilund-Carlsen","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"2024122016293922200_fcae435-B72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00259-019-04564-5","article-title":"Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer\u2019s disease: Why it is time to abandon the approach","volume":"47","author":"Alavi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2024122016293922200_fcae435-B73","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3233\/JAD-215275","article-title":"Aducanumab (marketed as Aduhelm) approval is likely based on misinterpretation of PET imaging data","volume":"84","author":"Hoilund-Carlsen","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"2024122016293922200_fcae435-B74","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003","article-title":"The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component","volume":"23","author":"Klunk","year":"2003","journal-title":"J Neurosci"},{"issue":"4","key":"2024122016293922200_fcae435-B75","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3233\/JAD-190220","article-title":"18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer\u2019s disease and mild cognitive impairment evaluation: A global quantitative analysis","volume":"70","author":"Khosravi","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"17","key":"2024122016293922200_fcae435-B76","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.286.17.2120","article-title":"Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome","volume":"286","author":"Silverman","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"2024122016293922200_fcae435-B77","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.36.10.1390","article-title":"Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type","volume":"36","author":"Grady","year":"1986","journal-title":"Neurology"},{"issue":"1","key":"2024122016293922200_fcae435-B78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1385\/JMN:16:1:41","article-title":"Correlation of the clinical severity of Alzheimer\u2019s disease with an aberration in mitochondrial DNA (mtDNA)","volume":"16","author":"Brown","year":"2001","journal-title":"J Mol Neurosci"},{"issue":"4","key":"2024122016293922200_fcae435-B79","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/WCO.0b013e32832d93c7","article-title":"Mapping brain beta-amyloid","volume":"22","author":"Jagust","year":"2009","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"2024122016293922200_fcae435-B80","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(00)81109-5","article-title":"Neuroplasticity failure in Alzheimer\u2019s disease: Bridging the gap between plaques and tangles","volume":"24","author":"Mesulam","year":"1999","journal-title":"Neuron"},{"issue":"Pt 11","key":"2024122016293922200_fcae435-B81","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer\u2019s disease","volume":"129","author":"Engler","year":"2006","journal-title":"Brain"},{"issue":"Pt 11","key":"2024122016293922200_fcae435-B82","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/brain\/awl281","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer\u2019s disease","volume":"129","author":"Klunk","year":"2006","journal-title":"Brain"},{"issue":"Pt 3","key":"2024122016293922200_fcae435-B83","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","article-title":"11C PiB and structural MRI provide complementary information in imaging of Alzheimer\u2019s disease and amnestic mild cognitive impairment","volume":"131","author":"Jack","year":"2008","journal-title":"Brain"},{"issue":"3","key":"2024122016293922200_fcae435-B84","first-page":"250","article-title":"FDG- and amyloid-PET in Alzheimer\u2019s disease: Is the whole greater than the sum of the parts?","volume":"55","author":"Mosconi","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"9","key":"2024122016293922200_fcae435-B85","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1002\/alz.14108","article-title":"Considering challenges for the new Alzheimer\u2019s drugs: Clinical, population, and health system perspectives","volume":"20","author":"Walsh","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2024122016293922200_fcae435-B86","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jalz.2014.12.007","article-title":"Alzheimer\u2019s disease first symptoms are age dependent: Evidence from the NACC dataset","volume":"11","author":"Barnes","year":"2015","journal-title":"Alzheimers Dement"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcae435\/60939394\/fcae435.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/6\/6\/fcae435\/60939394\/fcae435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/6\/6\/fcae435\/60939394\/fcae435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T11:30:08Z","timestamp":1734694208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcae435\/7915707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcae435","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024]]},"article-number":"fcae435"}}